KUALA LUMPUR, March 6 -- The Sabin Vaccine Institute (Sabin) has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID) to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines.
The vaccines will be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers and other at-risk populations.
According to a statement, Sabin will receive US$5.3 million to manufacture Ebola Sudan and Marburg vaccines for the VRC. (US$1 = RM4.17)
Under an existing Research Collaboration Agreement with NIAID VRC, Sabin plans to continue the development of two individual vaccines against Ebola Sudan and Marburg viruses, building on VRC’s work to date.
In September, Sabin announced an initial award of US$20.5 million with options for an additional US$107 million from the Biomedical Advanced Research and Development Authority (BARDA) to further support the two vaccine development programmes.
The BARDA contract followed an August agreement between Sabin and GSK, under which Sabin exclusively licensed the technology for candidate vaccines against Ebola Zaire, Ebola Sudan and Marburg viruses and acquired certain patent rights specific to these vaccines.
Sabin is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. More details at www.sabin.org.
-- BERNAMA
No comments:
Post a Comment